



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2024

Date: 19<sup>th</sup> April, 2024

**The President**  
**Corporate Relationship Department**  
**BSE Limited**  
**Phiroze Jeejeebhoy Towers,**  
**25<sup>th</sup> Floor, Dalal Street,**  
**Mumbai 400 001**

**The Vice President,**  
**Listing Compliance Department,**  
**National Stock Exchange of India Limited,**  
**Exchange Plaza, 5<sup>th</sup> Floor**  
**Plot No. C/2, G-Block,**  
**Bandra Kurla Complex, Bandra (E),**  
**Mumbai 400 051**

**ISIN: INE915B01019, INE915B07024**  
**BSE Scrip Code: 532305, 957989**

**NSE Symbol: INDSWFTLAB**

### **SUBJECT: INTIMATION UNDER REGULATION 30 REGARDING INCORPORATION OF WHOLLY OWNED SUBSIDIARY**

Dear Sir/Ma'am,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 (hereinafter "SEBI Listing Regulations") read with Para A-Part A of Schedule III of the SEBI Listing Regulations, including any statutory modification(s), amendment(s) or re-enactment(s) thereof for the time being in force we hereby inform you that Ind-Swift Laboratories Limited has approved the incorporation of a wholly owned subsidiary ("WOS") in Dubai, United Arab Emirates (UAE) in the name and style of "Ind-Swift (Dubai) Ltd." or such other name as may be approved by the concerned authorities of the UAE.

The Company shall further intimate on receipt of Certificate of Incorporation as and when the same is received by the Company.

Further the details required under SEBI Master Circular issued vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 is enclosed herewith as Annexure I.

The above is for your information and records.

With Regards,  
For **IND-SWIFT LABORATORIES LTD.**



**PARDEEP VERMA**  
**VP-CORPORATE AFFAIRS &**  
**COMPANY SECRETARY**



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



### Annexure I

S. No.	Particulars	Details
1.	Name of the Target Company, details in brief such as size, turnover, etc.	Name: Ind-Swift (Dubai) Ltd. or such other name as may be approved by the concerned authorities of the UAE  size/Turnover: Not applicable (since it is a new entity which is yet to be incorporated)
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	The investment in the wholly owned subsidiary would be a Related Party Transaction. The investment shall be made on arms’ Length basis.
3.	Industry to which the entity being acquired belongs	Pharmaceuticals
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The WOS intends to strategically invest in pharmaceutical and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures. Additionally, the Company aims to establish and operate pharmaceutical manufacturing units.
5.	Brief details of any governmental or regulatory approvals required for the acquisition;	The WOS is proposed to be incorporated in Dubai and is subject to regulatory approvals as per the laws of Dubai.
6.	Indicative time period for completion of the acquisition;	NA
7.	Nature of consideration - whether cash consideration or share swap and details of the same;	Subscription to 100% of the equity in WOS, to be paid in cash.
8.	Cost of acquisition or the price at which the shares are acquired	NA
9.	Percentage of shareholding / control acquired and / or number of shares acquired;	100%
10.	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Not Applicable since the company is yet to be incorporated.